重组人类促红细胞生成素治疗慢性肾功能衰竭贫血

Treatment of Anemia in Patients of Chronic Renal Failure with Recombinant Human Erythropoietin

应用重组人类促红细胞生成素（ｒＨｕＥＰＯ）治疗１６例慢性肾功能衰竭（ＣＲＦ）维持血液透析（ＨＤ）患者的贫血，８周后，贫血明显改善，生活质量提高。共观察１２周。血红蛋白（Ｈｂ）由５１．４±９．３ｇ／Ｌ增至８８．４±４．７ｇ／Ｌ（Ｐ＜０．００１），红细胞比积（Ｈｃｔ）由１７．５±２．８％增至３１．７±４．２％（Ｐ＜０．００１）。

cases of chronic renal failure,having been maintained by hemodialysis,were treated with recombinant human erythropoietin.The results show that there is correction of anemia and improvement of quality of life after 8 weeks.Hemoglobin has increased from 51.4±9.3g/L to 88.4±4.7 g/L(P<0.001),and hematocrit from 17.5±2.8% to 31. 7±4.3%(P<0.001).Some adverse effects,including hypertension,iron deficiency, hypercoagulability and influence on hemodialysis,were observed.